
Epigenetic Therapy Silences Hepatitis B Virus in Early Trials
A new epigenetic therapy, CRMA-1001, has shown promise in silencing the hepatitis B virus (HBV) by adding chemical tags to viral DNA rather than cutting it. Developed by nChroma Bio and Italian researchers, the treatment targets both free-floating and integrated HBV DNA in the liver. Preclinical tests in human cells, mice, and monkeys yielded strong results with minimal side effects. A clinical trial has now begun in Hong Kong and New Zealand, with the first patient treated in January 2026. This approach aims to offer a potential cure for the 250 million people globally affected by chronic HBV, avoiding the cancer risks associated with traditional gene-editing methods.












